FDA Approves First Oral Pill to Prevent COVID-19 Infection After Exposure

The agonizing wait after a household member tests positive for COVID-19—wondering if and when symptoms will start—has been a persistent frustration. While antiviral treatments exist for those who are already sick, previous attempts to use them preventatively failed in clinical trials, leaving exposed individuals with no oral pharmaceutical defense. Now, that gap has been closed.[5]

The U.S. Food and Drug Administration has officially approved Xocova (ensitrelvir) as the first oral antiviral indicated for post-exposure prophylaxis of COVID-19. Authorized for adults and adolescents 12 years and older, the medication is designed to be taken after close contact with an infected individual to stop the virus from taking hold.[3][4]

Developed by Shionogi, the drug works as a 3CL protease inhibitor. The SARS-CoV-2 virus relies on its main protease enzyme to replicate and spread throughout the body. By selectively blocking this enzyme, the medication halts viral replication during the critical window between exposure and the onset of symptoms, neutralizing the threat before the patient becomes ill.[1][3]

The FDA's decision was anchored by data from the Phase 3 SCORPIO-PEP trial, published in The New England Journal of Medicine. The study enrolled over 2,000 participants who had a household member with symptomatic COVID-19. Crucially, nearly all participants had some baseline immunity from prior infection or vaccination, reflecting the current real-world landscape.[1][2]

When administered within 72 hours of the household member's symptom onset, the antiviral reduced the risk of the exposed individual developing symptomatic COVID-19 by 67%. Only 2.9% of participants who took the drug developed symptoms within 10 days, compared to 9.0% of those in the placebo group.[1][3]

For patients, the preventative treatment involves a five-day oral regimen. It requires taking three 125-milligram tablets on the first day to establish a loading dose, followed by a single tablet daily on days two through five. Because the 72-hour initiation window is strict, rapid testing of the sick household member and immediate clinical evaluation for the exposed contact are essential.[1][3]

In clinical trials, the medication demonstrated a safety profile comparable to a placebo. The most commonly reported side effects were mild and included headache, diarrhea, and cough. Notably, the drug did not cause the altered taste sensation that has been a frequent complaint with other COVID-19 antivirals.[1][3]

However, prescribing clinicians and patients must navigate potential drug interactions. The medication is a moderate inhibitor of the CYP3A enzyme pathway in the liver, meaning it can affect how the body metabolizes certain other drugs. Patients taking specific medications, such as certain statins or anticonvulsants, will need their doctor to review their chart for temporary dose adjustments.[1]

While the clinical trials focused on household contacts, infectious disease experts note the drug's potential utility in other high-risk environments. Outbreaks in nursing homes, long-term care facilities, and acute care hospitals could be mitigated by deploying the medication to vulnerable residents immediately after a case is identified.[5]

The introduction of an effective oral prevention option marks a practical milestone in managing COVID-19. By shifting the paradigm from purely reactive treatment to proactive prevention, high-risk individuals now have a clinically validated tool to protect themselves in the immediate aftermath of a known exposure.[5]